An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination

An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination | Texila Journal

Publication Details

Journal: Texila international journal of public health
Published: 2024-12-26
DOI: https://doi.org/10.21522/tijph.2013.12.04.art032
Citations: 2
Primary Topic: Diabetes, Cardiovascular Risks, and Lipoproteins
Type: article
Field-Weighted Citation Impact: 0.72

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination

Dec 26, 2024

2 citations

Texila international journal of public health

Diabetes, Cardiovascular Risks, and Lipoproteins

0.72

article

An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination

December 26, 2024article en

2 citations

Abstract

Texila international journal of public healthVol. 12(04)

Openalex Percentile: Top 23%

Diabetes, Cardiovascular Risks, and Lipoproteins

0.72

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.